Institutes for Systems Genetics, West China Hospital
Copyright @ 2022 ISG. All Rights Reserved.
ncRNA name
hsa-miR-363
Specific or universal ncRNAs
Universal ncRNAs
Class
MicroRNA
Biomarker
No
Biomarker application
Upstream regulatory factors
Not available
Downstream target
LATS2
Cancer name
Ovarian Cancer
Cancer site
Ovary
Treatment type
Chemotherapy
Drug
Paclitaxel
Impact of wild-type ncRNA on chemotherapy resistance
Up
Impact of knockdown of ncRNA on chemotherapy resistance
Impact of overexpression of ncRNA on chemotherapy resistance
ncRNA differential expression in
cancer
patients vs. healthy people
Not available
Number of patients
Not available
Male patients
Not available
Female patients
Not available
Age range and number
Not available
PMID
Description
MiR-363 confers taxane resistance in ovarian cancer by targeting the Hippo pathway member, LATS2.
Tissue resource
tumor specimens from patients with ovarian cancer
human ovarian serous cancer cell lines SKOV3
ovarian serous cancer cell lines KF
clear cell carcinoma cell lines OVTOKO
Experiment
qRT-PCR,Western blot,Luciferase reporter assay
Institute
Hokkaido University Hospital
National Defence Medical College
Country
Japan
Continent
Asia
Institutes for Systems Genetics, West China Hospital
Copyright @ 2022 ISG. All Rights Reserved.